Protalix BioTherapeutics
PLX
34 hedge funds and large institutions have $5.61M invested in Protalix BioTherapeutics in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
11% more call options, than puts
Call options by funds: $1.57M | Put options by funds: $1.42M
3% more funds holding
Funds holding: 33 → 34 (+1)
0.17% more ownership
Funds ownership: 9.51% → 9.68% (+0.17%)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
26% less capital invested
Capital invested by funds: $7.58M → $5.61M (-$1.97M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$643K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$387K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$66.1K |
| 4 |
IWM
IHT Wealth Management
Chicago,
Illinois
|
+$50.5K |
| 5 |
DC
Davenport & Co
Richmond,
Virginia
|
+$36.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$509K |
| 2 |
Walleye Capital
New York
|
-$192K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$138K |
| 4 |
Walleye Trading
New York
|
-$82.1K |
| 5 |
Renaissance Technologies
New York
|
-$57K |
PLX Hedge Fund Activity: Q3 2021 in Review
34 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q3 2021, worth a combined $5.61M — down 26% from $7.58M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new PLX positions and 5 closed out — a net gain of 1 holder — while 10 added to existing stakes and 10 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $643K. The largest seller was Bridgeway Capital Management, cutting an estimated $509K.
- 34 institutional investors held Protalix BioTherapeutics (PLX) as of Q3 2021, up from 33 in Q2 2021.
- Funds reported $5.61M of Protalix BioTherapeutics stock for Q3 2021, down 26% quarter-over-quarter.
- 6 funds opened new Protalix BioTherapeutics positions in Q3 2021 and 5 closed out, a net change of +1 holder.
- The largest Protalix BioTherapeutics buyer in Q3 2021 was Morgan Stanley, an estimated $643K added.
- The largest Protalix BioTherapeutics seller in Q3 2021 was Bridgeway Capital Management, an estimated $509K sold.
Based on aggregated 13F filings for Q3 2021.